Aden K.Y. CHAN (陈家贤)MB ChB (CUHK), PhD (CUHK)adenchan@cuhk.edu.hk Aden Chan is a Clinical Lecturer in Department of Anatomical and Cellular Pathology in The Chinese University of Hong Kong. He received his medical degree in The Chinese University of Hong Kong and completed his Ph.D. in the field of molecular pathology in lower grade gliomas under the supervision of Professor H. K. Ng in Department of Anatomical and Cellular Pathology, The Chinese University Hong Kong. He has been actively engaged in the teaching of various pathology courses for medical students, Chinese medicine students, and postgraduate MSc students. His research interests include identification of clinically relevant biomarkers and development of prognostic models in diffuse gliomas.
Ongoing Grants
Micro-Module Courseware Development Grant, Basic Scheme (CUHK) 2016, “Development of micro-modules for neuro-oncology” (PI) (HKD 80,000 2016-2017)

Selected Publications First / corresponding authored papers in brain tumors
Chan AK (corresponding) , Zhang RR, Aibaidula A, Shi ZF, Chen H, Mao Y, Ng HK. BRAF mutation marks out specific subgroups of glioma. Glioma. 2018; 1:168-74.

Li YX, Aibaidula A, Shi Z, Chen H, Li KK, Chung NY, Yang RR, Chan DT, Poon WS, Lee KLR, Mao Y, Wu J, Chan AK (co-corresponding), Zhou L, Ng HK. Oligodendrogliomas in pediatric and teenage patients only rarely exhibit molecular markers and patients have excellent survivals. J Neurooncol. 2018 (in press).

Aibaidula A, Chan AK (co-first), Shi ZF, Li YX, Zhang RR, Yang RR, Li KK, Chung NY, Wu JS, Chen H, Ng HK. Adult IDH wild-type lower grade gliomas should be further stratified. Neuro Oncol. 2017;19(10):1327-1337.

Zhang ZY, Chan AK (co-first), Ding XJ, Li YX, Zhang RQ, Chen LC, Wang Y, Xiong J, Ng HK, Yao Y, Zhou LF. Glioma groups classified by IDH and TERT promoter mutations remain stable among primary and recurrent gliomas. Neuro Oncol. 2017;19(7):1008-1010.

Chan AK , Mao Y, Ng HK. TP53 and histone H3.3 mutations in triple-negative lower-
grade gliomas. N Engl J Med. 2016;375(22):2206-2208.

Li YX, Shi Z, Aibaidula A, Chen H, Tang Q, Li KK, Chung NY, Chan DT, Poon WS, Mao Y, Wu JS, Zhou LF, Chan AK (co-corresponding), Ng HK. Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic. Oncotarget. 2016 4;7(40):64615-64630.

Zhang RQ, Shi Z, Chen H, Chung NY, Yin Z, Li KK, Chan DT, Poon WS, Wu J, Zhou L, Chan AK (co-corresponding), Mao Y, Ng HK. Biomarker-based prognostic stratification of young adult glioblastoma. Oncotarget. 2016;7(4):5030-41.

Chan AK , Yao Y , Zhang Z, Shi Z, Chen L, Chung NY, Liu JS, Li KK, Chan DT, Poon WS, Zhou LF, Ng HK. Combination genetic signature stratifies lower-grade gliomas better than histological grade. Oncotarget. 2015;6(25):20885-901.

Zhang Z, Chan AK (co-first), Ding X, Qin Z, Hong CS, Chen L, Zhang X, Wang Y, Wang Y, Zhou LF, Zhuang Z, Ng HK, Yan H, Yao Y, Mao Y. TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas. Oncotarget. 2015;6(28):24871-83.

Chan AK , Yao Y, Zhang Z, Chung NY, Liu JS, Li KK, Shi Z, Chan DT, Poon WS, Zhou LF, Ng HK. TERT promoter mutations contribute to subset prognostication of lower grade gliomas. Mod Pathol. 2015;28(2):177-86.

Chan AK , Pang JC, Chung NY, Li KK, Poon WS, Chan DT, Shi Z, Chen L, Zhou L, Ng HK. Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors. Mod Pathol. 2014;27(3):332-42.

Sun ZL, Chan AK (co-first), Chen LC, Tang C, Zhang ZY, Ding XJ, Wang Y, Sun CR, Ng HK, Yao Y, Zhou LF. TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline. Int J Clin Exp Pathol. 2015;8(9):11485-94.

Zhang Z, Chan AK (co-first), Ng HK, Ding X, Li Y, Shi Z, Zhu W, Zhong P, Wang Y, Mao Y, Zhou LF. Surgically treated incidentally discovered low-grade gliomas are mostly IDH mutated and 1p19q co-deleted with favorable prognosis. Int J Clin Exp Pathol. 2014;7(12):8627-8636.

Yao Y, Chan AK (co-first), Qin ZY, Chen LC, Zhang X, Pang JC, Li HM, Wang Y, Mao Y, Ng HK, Zhou LF. Mutation analysis of IDH1 in paired gliomas revealed IDH1 mutation was not associated with malignant progression but predicted longer survival. PLoS One. 2013;8(6):e67421.

Co-authored papers in brain tumors
Yang RR, Aibaidula A, Wang WW, Chan AK, Shi ZF, Zhang ZY, Chan DTM, Poon WS, Liu XZ, Li WC, Zhang RQ, Li YX, Chung NY, Chen H, Wu J, Zhou L, Li KK, Ng HK. Pediatric low-grade gliomas can be molecularly stratified for risk. Acta Neuropathol. 2018; 136(4):641-655.

Vuong HG, Altibi AMA, Duong UNP, Ngo HTT, Pham TQ, Chan AK, Park CK, Fung KM, Hassell L. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data. Crit Rev Oncol Hematol. 2017;120:1-9.

Lassaletta A, Mistry M, Ramaswamy V, Honnorat M, Zapotocky M, Krishnatry R, Stucklin AG, Zhukova N, Arnaldo A, Ryall S, Ling C, McKeown T, Cruz O, Torres Gomez-Pallete C, Ho C, Packer R, Tatevossian R, Ellison D, Harreld J, Dalton J, Mulcahy-Levy J, Foreman N, Karajanis M, Rao AN, Kieran M, Ligon K, Garre ML, Nozza P, Mascelli S, Raso A, Mueller S, Nicolaides T, Jouvet A, Perbert R, Vasiljevic A, Frappaz D, Leary S, Crane C, Chan AK, Ng HK, Shi ZF, Mao Y, Finch E, Eisenstat D, Wilson B, Carret AS, Hauser P, Sumerauer D, Larouche V, Fleming A, Zelcer S, Jabado N, Bartels U, Huang A, Bouffet E, Hawkins C, Tabori U. Therapeutic and Prognostic Implications of BRAF-V600E in Pediatric Low Grade Gliomas. J Clin Oncol. 2017;35(25):2934-2941.

Li KK, Qi Y, Xia T, Chan AK, Zhang ZY, Aibaidula A, Zhang R, Zhou L, Yao Y, Ng HK. The kinesin KIF14 is overexpressed in medulloblastoma and downregulation of KIF14 suppressed tumor proliferation and induced apoptosis. Lab Invest. 2017;97(8):946-961.

Li KK, Yang L, Pang JC, Chan AK, Zhou L, Mao Y, Wang Y, Lau KM, Poon WS, Shi Z, Ng HK. MIR-137 suppresses growth and invasion, is downregulated in oligodendroglial tumors and targets CSE1L. Brain Pathol. 2013;23(4):426-39.